Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study

Inclusion Criteria

• •Age ≥ 18 years
• •WHO PS 0-2
• •Histological or cytological confirmation of non-small cell lung cancer or an 18F-FDG-positive, growing mass on CT-thorax suggestive of NSCLC.
• •Stage IIIA or IIIB
• •Patients with extensive mediastinal lymph node involvement (such as N3), or large primary tumour size
• •Adequate pulmonary function estimated by flow volume curves
• •Life expectancy of at least 6 months
• •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
• •Planned for 25 x 2.4 Gy, with concomitant chemotherapy
• •Before patient registration, written informed consent will be obtained.